JP2021531273A5 - - Google Patents
Info
- Publication number
- JP2021531273A5 JP2021531273A5 JP2021502476A JP2021502476A JP2021531273A5 JP 2021531273 A5 JP2021531273 A5 JP 2021531273A5 JP 2021502476 A JP2021502476 A JP 2021502476A JP 2021502476 A JP2021502476 A JP 2021502476A JP 2021531273 A5 JP2021531273 A5 JP 2021531273A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- xrpd
- solid form
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024063946A JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862700064P | 2018-07-18 | 2018-07-18 | |
| US62/700,064 | 2018-07-18 | ||
| PCT/US2019/042226 WO2020018680A1 (en) | 2018-07-18 | 2019-07-17 | Solid forms of an azolopyrimidine compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063946A Division JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021531273A JP2021531273A (ja) | 2021-11-18 |
| JP2021531273A5 true JP2021531273A5 (cg-RX-API-DMAC7.html) | 2022-07-26 |
| JP7522720B2 JP7522720B2 (ja) | 2024-07-25 |
Family
ID=69164033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021502476A Active JP7522720B2 (ja) | 2018-07-18 | 2019-07-17 | アゾロピリミジン化合物の固体形態 |
| JP2024063946A Withdrawn JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024063946A Withdrawn JP2024083556A (ja) | 2018-07-18 | 2024-04-11 | アゾロピリミジン化合物の固体形態 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11993584B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3823614A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7522720B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102826213B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113015523B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019306582B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3106366A1 (cg-RX-API-DMAC7.html) |
| MY (1) | MY205549A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12021550084A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202100267TA (cg-RX-API-DMAC7.html) |
| TW (1) | TWI835821B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020018680A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| BR112021022538A2 (pt) | 2019-06-06 | 2021-12-28 | Arcus Biosciences Inc | Processos para preparar compostos de aminopirimidina |
| TW202421150A (zh) | 2022-09-14 | 2024-06-01 | 美商阿克思生物科學有限公司 | 艾魯美冷之分散體 |
| WO2024097736A1 (en) | 2022-11-02 | 2024-05-10 | Arcus Biosciences, Inc. | Processes for preparing azolopyrimidine compounds |
| WO2025193759A1 (en) | 2024-03-12 | 2025-09-18 | Gilead Sciences, Inc. | Solid forms of an azolopyrimidine compound |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474599A (en) | 1982-07-14 | 1984-10-02 | The Dow Chemical Company | 1-(Pyridyl)-1H-1,2,3-triazole derivatives, and use as herbicidal agents |
| JP4286146B2 (ja) | 2001-12-18 | 2009-06-24 | メルク エンド カムパニー インコーポレーテッド | メタボトロピックグルタミン酸受容体−5のヘテロアリール置換ピラゾール系調節剤 |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| JP5238936B2 (ja) | 2005-03-25 | 2013-07-17 | ジーアイティーアール,インク. | Gitr結合分子およびその使用 |
| KR101704734B1 (ko) | 2005-07-01 | 2017-02-09 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| PT2175884T (pt) | 2007-07-12 | 2016-09-21 | Gitr Inc | Terapias de combinação empregando moléculas de ligação a gitr |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| MX356367B (es) | 2008-12-09 | 2018-05-25 | Genentech Inc | Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t. |
| WO2010077582A1 (en) * | 2008-12-16 | 2010-07-08 | Merck Sharp & Dohme Corp. | Triazole derivatives for treatment of alzheimer's disease |
| IN2015DN02826A (cg-RX-API-DMAC7.html) | 2009-09-03 | 2015-09-11 | Merck Sharp & Dohme | |
| DK2510010T3 (en) | 2009-12-10 | 2015-12-14 | Hoffmann La Roche | Antibodies that bind to human CSF1R extracellular domain 4 and their use |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| CN102918061B (zh) | 2010-03-05 | 2016-06-08 | 霍夫曼-拉罗奇有限公司 | 针对人csf-1r的抗体及其用途 |
| RU2617971C2 (ru) | 2010-03-05 | 2017-04-28 | Ф.Хоффманн-Ля Рош Аг | Антитела против csf-1r человека и их применение |
| EP3943154A1 (en) | 2010-05-04 | 2022-01-26 | Five Prime Therapeutics, Inc. | Antibodies that bind csf1r |
| NZ729044A (en) | 2010-09-09 | 2020-07-31 | Pfizer | 4-1bb binding molecules |
| CA2833636A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| MX356337B (es) | 2011-12-15 | 2018-05-23 | Hoffmann La Roche | Anticuerpos contra csf-1r humano y sus usos. |
| MX2014008961A (es) | 2012-02-06 | 2014-10-14 | Genentech Inc | Composiciones y metodos para utilizar inhibidores de csf1r. |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| KR20150018533A (ko) | 2012-05-11 | 2015-02-23 | 파이브 프라임 테라퓨틱스, 인크. | 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014048065A1 (en) * | 2012-09-28 | 2014-04-03 | Merck Sharp & Dohme Corp. | Triazolyl derivatives as syk inhibitors |
| TWI641595B (zh) | 2013-07-17 | 2018-11-21 | 日商大塚製藥股份有限公司 | 氰基三唑化合物類 |
| MX389798B (es) * | 2017-01-20 | 2025-03-20 | Arcus Biosciences Inc | Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer. |
| CA3090922A1 (en) | 2018-02-16 | 2019-08-22 | Arcus Biosciences, Inc. | Dosing with an azolopyrimidine compound |
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| BR112021022538A2 (pt) | 2019-06-06 | 2021-12-28 | Arcus Biosciences Inc | Processos para preparar compostos de aminopirimidina |
-
2019
- 2019-07-17 EP EP19838123.8A patent/EP3823614A4/en active Pending
- 2019-07-17 CA CA3106366A patent/CA3106366A1/en active Pending
- 2019-07-17 MY MYPI2021000254A patent/MY205549A/en unknown
- 2019-07-17 KR KR1020217004714A patent/KR102826213B1/ko active Active
- 2019-07-17 US US17/260,847 patent/US11993584B2/en active Active
- 2019-07-17 CN CN201980058983.5A patent/CN113015523B/zh active Active
- 2019-07-17 JP JP2021502476A patent/JP7522720B2/ja active Active
- 2019-07-17 SG SG11202100267TA patent/SG11202100267TA/en unknown
- 2019-07-17 WO PCT/US2019/042226 patent/WO2020018680A1/en not_active Ceased
- 2019-07-17 AU AU2019306582A patent/AU2019306582B2/en active Active
- 2019-07-18 TW TW108125369A patent/TWI835821B/zh active
-
2021
- 2021-01-13 PH PH12021550084A patent/PH12021550084A1/en unknown
-
2024
- 2024-04-11 JP JP2024063946A patent/JP2024083556A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7861083B2 (ja) | Fak阻害剤およびその併用薬物 | |
| JP2023530456A5 (cg-RX-API-DMAC7.html) | ||
| CA3016826C (en) | Salt of pyridinyl amino pyrimidine derivative, preparation method therefor, and application thereof | |
| JP2015509537A5 (cg-RX-API-DMAC7.html) | ||
| KR102731401B1 (ko) | 키나아제 억제제로 사용되는 화합물 및 이의 응용 | |
| CN101878218A (zh) | 埃克替尼盐酸盐及其制备方法、晶型、药物组合物和用途 | |
| JP2016513704A5 (cg-RX-API-DMAC7.html) | ||
| JP2022507267A5 (cg-RX-API-DMAC7.html) | ||
| JP6894917B2 (ja) | ピリジニルアミノピリミジン誘導体のメシル酸塩の結晶形、その製造方法及びその使用 | |
| CA2862704C (en) | Ribonucleotide reductase inhibitors and methods of use | |
| JP2008528466A5 (cg-RX-API-DMAC7.html) | ||
| CN110396088A (zh) | Hpk1激酶抑制剂、制备方法及其应用 | |
| JP2014524476A5 (cg-RX-API-DMAC7.html) | ||
| AU2022380979A1 (en) | Pparg inverse agonists and uses thereof | |
| JP2017507175A5 (cg-RX-API-DMAC7.html) | ||
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| JP2021513965A5 (cg-RX-API-DMAC7.html) | ||
| TW202412760A (zh) | Cbl-b抑制劑及其使用方法 | |
| AU2006216266A2 (en) | Quinazoline derivative having tyrosine kinase inhibitory activity | |
| CN105254699B (zh) | 4‑(4’‑三氟甲基)苯基‑2‑去氢表雄酮‑17’‑腙噻唑及其制备方法和用途 | |
| WO2007096618A2 (en) | 2-[3h-thiazol-2-ylidinemethyl]pyridines and related compounds and their use | |
| JP2023506066A (ja) | 5-ブロモピリジン-3-イル-3-デオキシ-3-[4-(3,4,5-トリフルオロフェニル)-1h-1,2,3-トリアゾール-1-yl]-1-チオ-アルファ-d-ガラクトピラノシド及びその結晶形を調製するための大規模方法 | |
| JP2021522348A5 (cg-RX-API-DMAC7.html) | ||
| CN102133217B (zh) | 一类以n为桥键的哒嗪酮类化合物在制备抗肿瘤的药物中的用途 | |
| CN113603713B (zh) | 一种取代的硼酸酯化合物的制备方法及其晶型 |